BCDANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
BioCardia, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$0.90−0.02 (-2.46%)
Close on Oct 19, 2026
- Market cap
- $10.85M
- P/E (TTM)
- –
- Dividend yield
- –
BioCardia, Inc. revenue by segment
By business segment
By product or service
| Revenue | TTM Q4 23 | TTM Q3 23 | TTM Q2 23 | TTM Q1 23 | TTM Q4 22 | TTM Q3 22 | TTM Q2 22 | TTM Q1 22 | TTM Q4 21 | TTM Q3 21 | TTM Q2 21 | TTM Q1 21 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Collaboration Agreement [Member] | $477.00K | $570.00K | $423.00K | $1.35M | $1.35M | $1.32M | $1.93M | $1.03M | $1.01M | $981.00K | $187.00K | $145.00K | 100.0% | -64.6% |
| Product [Member] | $0 | $0 | $2.00K | $2.00K | $3.00K | $3.00K | $2.00K | $2.00K | $1.00K | $1.00K | $8.00K | $8.00K | 0.0% | -100.0% |
By region
From the segment and revenue-disaggregation notes of BioCardia's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.